Reflections and speculations on refractory migraine: Why do some patients fail to improve with currently available therapies?

Headache

Volumn 48, Issue 6, 2008, Pages 828-837

  Dodick, David W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chronic migraine; Refractory

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYANOCOBALAMIN; DIHYDROERGOTAMINE MESILATE; MAGNESIUM OXIDE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PETASITES HYBRIDUS EXTRACT; RIBOFLAVIN; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UBIDECARENONE; VALPROATE SEMISODIUM;

ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DRUG EFFECT; EPILEPSY; GENETIC HETEROGENEITY; HUMAN; MAJOR DEPRESSION; MIGRAINE; NEUROIMAGING; NOCICEPTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATIENT COMPLIANCE; PATIENT EDUCATION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TACHYPHYLAXIS; TREATMENT FAILURE; UPREGULATION;

COMBINED MODALITY THERAPY; HEADACHE DISORDERS; HUMANS; MIGRAINE DISORDERS; PAIN, INTRACTABLE; TREATMENT FAILURE;

EID: 44849110261     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2008.01158.x     Document Type: Review

References (28)

1. Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick DW. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006 26 : 1168 1170.
2. Dodick DW, Silberstein SD. Migraine prevention. Pract Neurol. 2007 7 : 383 393.
3. Silberstein SD, Dodick DW, Freitag F, et al. Pharmacological approaches to managing migraine and associated comorbidities - clinical considerations for monotherapy versus polytherapy. Headache. 2007 47 : 585 599.
4. Rains JC, Penzien DB, Lipchik GL. Behavioral facilitation of medical treatment for headache - part II: Theoretical models and behavioral strategies for improving adherence. Headache. 2006 46 : 1395 1403.
5. Breslau N, Davis GC. Migraine, major depression, and panic disorder: A prospective epidemiologic study of young adults. Cephalalgia. 1992 12 : 85 90.
6. Breslau N, Merikangas K, Bowden CL. Comorbidity of migraine and major affective disorders. Neurology. 1994 44 (10 Suppl. 7 S17 S22.
7. Baskin SM, Lipchik GL, Smitherman TA. Mood and anxiety disorders in chronic headache. Headache. 2006 46 (Suppl. 3 S76 S87.
8. Saper JR. Are you talking to me?" Confronting behavioral disturbances in patients with headache. Headache. 2006 46 (Suppl. 3 S151 S156.
9. Townsend CO, Bruce BK, Hooten WM, Rome JD. The role of mental health professionals in multidisciplinary pain rehabilitation programs. J Clin Psychol. 2006 62 : 1433 1443.
10. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001 89 : 107 110.
11. Meng ID, Cao L, From migraine to chronic daily headache: The biological basis of headache transformation. Headache. 2007 47 : 1251 1258.
12. Bigal ME, Lipton RB, Holland PR, Goadsby PJ. Obesity, migraine, and chronic migraine: Possible mechanisms of interaction. Neurology. 2007 68 : 1851 1861.
13. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004 62 : 788 790.
14. Zwart JA, Dyb G, Hagen K, Svebak S, Stovner LJ, Holmen J. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology. 2004 62 : 1540 1544.
15. Holland PR, Akerman S, Goadsby PJ. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther. 2005 315 : 1380 1385.
16. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: The effect of a 2-month drug-free period. Neurology. 2006 66 : 1894 1898.
17. Meng ID, Harasawa I. Chronic morphine exposure increases the proportion of on-cells in the rostral ventromedial medulla in rats. Life Sci. 2007 80 : 1915 1920.
18. Gardell LR, Wang R, Burgess SE, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci. 2002 22 : 6747 6755.
19. King T, Gardell LR, Wang R, et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain. 2005 116 : 276 288.
20. Mao J, Sung B, Ru-Rong J, Lim C. Chronic morphine induces downregulation of spinal glutamate transporters: Implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 2002 22 : 8312 8323.
21. Johnston IN, Milligan ED, Wieseler-Frank J, et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci. 2004 24 : 7353 7365.
22. Ossipov MH, Lai J, Vanderah TW, Porreca F. Induction of pain facilitation by sustained opioid exposure: Relationship to opioid antinociceptive tolerance. Life Sci. 2003 73 : 783 800.
23. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: Novel counter-regulators of opioid analgesia. Trends Neurosci. 2005 28 : 661 669.
24. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005 45 : 850 861.
25. Lötsch J, Geisslinger G. Current evidence for a modulation of nociception by human genetic polymorphisms. Pain. 2007 132 : 18 22.
26. Pauwels PJ. Diverse signaling by 5-hydroxytryptamine (5-HT) receptors. Biochem Pharmacol. 2000 60 : 1743 1750.
27. Craft RM, Mogil JS, Aloisi AM. Sex differences in pain and analgesia: The role of gonadal hormones. Eur J Pain. 2004 8 : 397 411.
28. Schulman EA, Lake AE III., Goadsby PJ, et al. Defining refractory migraine (RM) and refractory chronic migraine (RCM). Proposed criteria for the refractory headache special interests section of the American Headache Society. Headache. 2008 48 : 778 782.